Abstract:Aims/Purpose: Diabetic retinopathy is characterized by a chronic low‐grade retinal neuroinflammation triggered by diabetes and mediated, at least in part, by microglial cells. We previously showed that sitagliptin, an oral drug for type 2 diabetes, developed to inhibit dipeptidyl peptidase 4 (DPP4) and increase insulin release, can prevent retinal neuroinflammation in diabetic rat models and the LPS‐induced morphological changes of microglial cells in retinal organotypic cultures. However, the mechanisms underlying these effects are not clarified. We hypothesize that sitagliptin is able to directly inhibit microglia reactivity via Dpp4. Methods: BV‐2 microglia cell line was exposed to a non‐toxic dose of lipopolysaccharide (LPS, 0.1 μg/mL) in the presence or absence of 200 μM sitagliptin. The expression of Dpp4, iNOS, IL‐1 beta and TNF were assessed by Western Blot and/or RT‐qPCR. The BV‐2 phagocytic efficiency was assessed using fluorescent microbeads. The metabolic activity and proliferation of BV‐2 cells were assessed by resazurin assay and Edu staining, respectively. Dpp4 deletion in BV‐2 cells was generated using Crispr‐cas9 method. Results: Sitagliptin inhibited the LPS‐induced increase in protein levels of iNOS, IL‐1 beta and TNF to 39.9 ± 6.3%, 47.2 ± 8.1% and 34.0 ± 7.2%, respectively, comparing to LPS. Sitagliptin reduced the LPS‐induced increase in phagocytic efficiency by approximately 40%. Sitagliptin did not affect the metabolism and proliferation of BV‐2. BV‐2 cells express Dpp4. Dpp4 deletion does not affect the LPS‐induced phagocytosis but abrogated the effect of sitagliptin on the reduction of BV‐2 phagocytic efficiency (approx. 320% as in LPS). Conclusions: Sitagliptin exerts direct anti‐inflammatory effects on microglia, mediated by DPP4. These results suggest that sitagliptin can potentially be used in retinal pathologies characterized by microglia‐mediated neuroinflammation. Support. FCT‐Portugal: PEst UID/NEU/04539/2013, UIDB/04539/2020 and UIDP/04539/2020 and PTDC/NEU‐OSD/1113/2012. COMPETE‐FEDER.

Sitagliptin protects renal glomerular endothelial cells against high glucose-induced dysfunction and injury

Tripterygium glycoside protects diabetic kidney disease mouse serum-induced podocyte injury by upregulating autophagy and downregulating β-arrestin-1.

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevents High Glucose-Induced Apoptosis Via Activation of Amp-Activated Protein Kinase in Endothelial Cells

Emerging Protective Actions of PGC-1α in Diabetic Nephropathy

Vildagliptin Protects Endothelial Cells Against High Glucose-Induced Damage.

Sitagliptin ameliorates ER stress in diabetic kidney disease through upregulation of SIRT1

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway

SGLT2 Inhibitor—Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling Mechanism

Sitagliptin ameliorates renal tubular injury in diabetic kidney disease via STAT3-dependent mitochondrial homeostasis through SDF-1α/CXCR4 pathway

Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?

Anagliptin Ameliorates High Glucose- Induced Endothelial Dysfunction Via Suppression of NLRP3 Inflammasome Activation Mediated by SIRT1

Antioxidant Effects of DPP-4 Inhibitors in Early Stages of Experimental Diabetic Retinopathy

Sitagliptin Inhibits Vascular Inflammation Via the SIRT6-dependent Signaling Pathway.

The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory

Sitagliptin alleviates renal steatosis and endoplasmic reticulum stress in high fat diet-induced obese rats by targeting SREBP-1/CD36 signaling pathway

Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways

GLP-1 Receptor Agonist Improves Mitochondrial Energy Status and Attenuates Nephrotoxicity In Vivo and In Vitro

Liraglutide Inhibits Autophagy and Apoptosis Induced by High Glucose Through GLP-1R in Renal Tubular Epithelial Cells

Acute effects of sitagliptin on progenitor cells and soluble mediators in newly diagnosed type 2 diabetes

Sitagliptin, an anti‐diabetic drug, inhibits the pro‐inflammatory microglia reactivity via dipeptidyl peptidase‐4 ( DPP4 )